Back to dataset

UK Inflammatory Bowel Disease (IBD) audit: Round 4 (2012 - 2014) Data field description file adult biological therapies audit 2014

You're previewing the first 4 rows of this file.

Download this file
Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 Column 9
Health board / Trust name Sitename Number of patients with Crohn's disease entered at your site Patients with Crohn's disease given 160/80 mg of ADA at induction Response to treatment Remission achieved Patients with at least one adverse event Patients with Crohn's disease on concomittant therapy, 5-ASA at induction Patients with Crohn's disease, treatment effective and discontinued at follow-up
Name of Health Board / Trust Name of site No of Crohn's disease patients entered No of Crohn's disease patients given 160/80 mg of ADA at induction Percentage (%) of Crohn's disease patients with a HBI drop of >3 at any follow up between 10 and 14 weeks Percentage (%) of Crohn's disease patients with a HBI score of <4 at any follow up between 10 and 14 weeks Percentage of patients who experienced at least one adverse event Percentage of all patients with Crohn's disease on 5-ASA as a concomittant therapy at initial treatment Percentage of patients with Crohn's disease who had their treatment effective and discontinued at follow-up
text text integer integer (Percentage) integer (Percentage) integer (Percentage) integer (Percentage) integer (Percentage) integer (Percentage)
text text integer 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%)